# Phase II Study of Everolimus Beyond Progression

> **NCT02269670** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 3 (actual)

## Conditions studied

- Estrogen Receptor-positive Breast Cancer
- HER2-negative Breast Cancer
- Progesterone Receptor-positive Breast Cancer
- Recurrent Breast Cancer
- Stage IIIA Breast Cancer
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** everolimus
- **DRUG:** anastrozole
- **DRUG:** letrozole
- **DRUG:** tamoxifen citrate
- **DRUG:** fulvestrant
- **DRUG:** megestrol acetate

## Key facts

- **NCT ID:** NCT02269670
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-25
- **Primary completion:** 2021-01-25
- **Final completion:** 2021-01-25
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Slow to accrual
- **Last updated:** 2022-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269670, "Phase II Study of Everolimus Beyond Progression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02269670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*